DOCSLIB.ORG

List of Section 13F Securities, First Quarter 2003

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

OFFICIAL LIST OF SECTION 13(F) SECURITIES USER INFORMATION SHEET General This list of "Section 13(f) securities" as defined by Rule 13f-I (c) [17 CFR 240.13f-l(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [I5 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.1 3f-11 under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of Marchl5, 2003, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 30, 2003. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by [ Section 13(f)(l) and Rule 13f-I] thereunder. Features (1) Additions and Deletions: Revisions made to the list of Section 13(f) securities are indicated in a column titled "STATUS." The word "ADDED" in the status column opposite the name of a security indicates that the security has become a Section 13(f) security. The word "DELETED" in the status column opposite the name of a security indicates that the security ceases to be a 13(f) security since the date of the last list. (2) List of options: An asterisk is placed next to the name of any security having a listed option and each option is individually listed with its own CUSlP number immediately below the name of the security having the option. A manager reporting holdings of options on its Forml3F should use the CUSlP number of each option as to which holding are reported. CUSlP descriptions and numerical identification date (copyright 1969 through 1996, American Bankers Association) are used with permission. All rights are reserved. Run Date: 4/29/2003 ** List Of Section 13F Securities ** Page 1 Run Time: 1754 ISSUER NAME ISSUER DESCRIPTION STATUS ICOS VISION SYS COW N V ORD CELANESE AG ORD DAIMLERCHRYSLER AG ORD DAIMLERCHRYSLER AG CALL DAIMLERCHRYSLER AG PUT DEUTSCHE BANK AG NAMEN ORD DEUTSCHE BANK AG NAMEN CALL DEUTSCHE BANK AG NAMEN PUT TOTAL FMA ELF S A *W EXP 08/05/200 ACE LTD ORD ACE LTD CALL ACE LTD PUT ALPHASTAR INSURANCE GRP LTD SHS AMDOCS LTD ORD AMDOCS LTD CALL AMDOCS LTD PUT AMERICAN SAFETY INS GROUP LT om ANNUITY AND LIFE RE HLDGS om ANNUITY AND LIFE RE HLDGS CALL ANNUITY AND LIFE RE HLDGS PUT APEX SILVER MINES LTD ORD APEX SILVER MINES LTD CALL APEX SILVER MINES LTD PUT ARCH CAP GROUP LTD ORD ARCH CAP GROUP LTD CALL ARCH CAP GROUP LTD PUT BANK OF BERMUDA LTD SHS ACCENTURE LTD BERMUDA CL A ACCENTURE LTD BERMUDA CALL ACCENTURE LTD BERMCTDA PUT BUNGE LIMITED COM BUNGE LIMITED CALL BUNGE LIMITED PUT CENTRAL EUROPEAN MEDIA ENTRP CL A NEW CHINADOTCOM CORP CL A CHINADOTCOM COW CALL CHINADOTCOM CORP PUT CHINA WCHAI INTL LTD COM CHIPMOS TECH BERMUDA LTD SHS CLAXSON INTERACTIVE GROUP IN CL A DELETED CONSOLWATED WATER CO INC ORD Run Date: 4/29/2003 ** List Of Section 13F Securities ** Page 2 Run Time: 17:54 CUSlP NO ISSUER NAME ISSUER DESCRIPTION STATUS (324181 100 COOPER NDS LTD CL A G24 1 82 90 0 COOPER INDS LTD CALL G24 182 95 0 COOPER INDS LTD PUT G2519Y 10 8 CREDlCORP LTD COM G27545 10 5 DF CHINA TECHNOLOGY TNC om G28471 10 3 DSG INTL LTD ORD G29526 10 3 EK CHOR CHINA MOTORCYCLE CO COM (329539 15 5 ELAN PLC *W EXP 12/3 11'200 DELETED G29539 16 3 ELAN CORP PLC *W EXP 0813 11200 G30397 10 6 ENDURANCE SPECIALTY HLDGS LT SHS ADDED G31215 10 9 ESG RE LTD om DELETED G31611 109 XCELERA MC COM G31611 90 9 XCELERA INC CALL G31611 95 9 XCELERA MC PUT G32030 10 1 EURO TECH HOLDINGS CO LTD ORD G32030 11 9 EURO TECH HOLDINGS CO LTD * W EXP 021 141200 G3223R 10 8 EVEREST RE GROUP LTD COM G3223R 90 8 EVEREST RE GROUP LTD CALL G3223R 95 8 EVEREST RE GROUP LTD PUT G36535 10 5 FOSTER WHEELER LTD SHS G36535 90 5 FOSTER WHEELER LTD CALL G36535 95 5 FOSTER WHEELER LTD PUT (336738 10 5 FRESH DEL MONTE PRODUCE MC ORD (336738 90 5 FRESH DEL MONTE PRODUCE INC CALL G36738 95 5 FRESH DEL MONTE PRODUCE INC PUT G3682E 12 7 FRONTLINE LTD ORD (337260 10 9 GARMIN LTD ORD (337260 90 9 GARMIN LTD CALL G3 7260 95 9 GARMIN LTD PUT G3930E 10 1 GLOBALSANTAFE CORP SHS G3930E 90 1 GLOBALSANTAFE CORP CALL G3930E 95 1 GLOBALSANTAFE CORP PUT G39300 10 1 GLOBAL SOURCES LTD ORD G39320 10 9 GLOBAL-TECH APPLIANCES INC ORD G4388N 10 6 HELEN OF TROY CORP LTD COM G4388N 90 6 HELEN OF TROY COW LTD CALL G4388N 95 6 HELEN OF TROY CORP LTD PUT G4481U 10 6 HIGHWAY HLDGS LTD ORD G4776G 10 1 MGERSOLL-RAND COMPANY LTD CL A G4776G 90 1 LNGERSOLL-RAND COMPANY LTD CALL G4776G 95 1 INGERSOLL-RAND COMPANY LTD PUT Run Date: 4/29/2003 ** List Of Section 13F Securities ** Page 3 Run Time: 17% ISSUER NAME ISSUER DESCRIPTION STATUS INTERNATIONAL BRIQUETTES HLD ORD DELETED * INTERWAVE COMMUNCTNS INTL LT ORD INTERWAVE COMMUNCTNS INTL LT CALL INTERWAVE COMMUNCTNS INTL LT PUT * IPC HLDGS LTD ORD IPC HLDGS LTD CALL IPC HLDGS LTD PUT JINPAN INTL LTD ORD KNIGHTSBRIDGE TANKERS LTD ORD LJ INTL INC ORD LJ INTL INC * W EXP 04/ 151200 * LORAL SPACE & COMMUNICATIONS COM LORAL SPACE & COMMLTNICATIONS CALL LORAL SPACE & COMMUNICATIONS PUT * MARVELL TECHNOLOGY GROUP LTD ORD MARVELL TECHNOLOGY GROUP LTD CALL MARVELL TECHNOLOGY GROUP LTD PUT * MAX RE CAPITAL LTD HAMILTON SHS MAX RE CAPITAL LTD HAMILTON CALL MAX RE CAPITAL LTD HAMILTON PUT MIH LTD CL A DELETED MONTPELIER RE HOLDINGS LTD SHS * NABORS INDUSTRIES LTD SHS NABORS INDUSTRIES LTD CALL NABORS INDUSTRIES LTD PUT NEW CHINA HOMES LTD ORD NEW CHINA HOMES LTD *W EXP 03/09/200 * NOBLE CORPORATION SHS NOBLE CORPORATION CALL NOBLE CORPORATION PUT NORDIC AMERICAN TANKER SHIPP COM NOVEL DENIM HLDGS LTD ORD * OPENTVCORP CL A OPENTV CORP CALL OPENTV COW PUT ORIENT-EXPRESS HOTELS LTD CL A * OZMICRO INTERNATIONAL LIMITE ORD OZMICRO INTERNATIONAL LIMITE CALL 02MICRO INTERNATIONAI, LIMITE PUT * PARTNERRE LTD COM PARTNERRE LTD CALL Run Date: 4/29/2003 ** List Of Section 13F Securities ** Page 4 Run Time: 17:51 ISSUER NAME ISSUER DESCRIPTION STATUS PARTNERRE LI'D PUT I'EAK INTL. LTD ORD ' PLATlNlJh4 UNDERM'RITER HLDGS L COM PLATINUM LrNDERMJRITER HLDGS L CALL PLATINUM UNDERWRlTER HLDGS L PUT PXRE GROUP LTD CON Q1.40 XING UNIVERSAL TELEPHON ORD " RADlCA GAMES LTD ORD RADICA GAMES LTD CALL RADICA GAMES LTD PUT 'WNAISSANCE RE HLDGS LTD COM RENAISSANCE RE HLDGS LTD CALL RENAISSANCE RE HLDGS LTD PUT SCOTTISH ANNUITY & LIFE HLDG ORD " SEAGATE TECHNOLOGY SHS SEAGATE TECHNOLOGY CALL SEAGATE TECHNOLOGY PUT SEVEN SEAS PETROLEUM INC ORD DELETED SILVERSTAR HLDGS LTD ORD * SlNA CORP ORD SINA COW CALL SINA CORP PUT STEWART W P & CO LTD COM UTI WORLDWIDE INC ORD TIERS PRINCIPAL PROTECTED TR S&P 01-19 TR TIERS PRINCIPAL PROTECTED TR TIERS2000-2007 TIERS PRINCIPAL PROTECTED TR TIERS2000-20 14 TIERS PRINCIPAL PROTECTED TR TIERS 2000-20 13 TIERS PRINCIPAL PROTECTED TR S&P 2001 11 TR TIERS PRINCIPAL PROTECTED TR TIERS 200 1- 13 TIERS PRINCIPAL PROTECTED TR DJIA 2001-26 TIERS PRINCIPAL PROTECTED TR 2002- 1 TR CTF " HHILFIGER TOMMY CORP ORD HILFlGER TOMMY CORP CALL HILFlGER TOMMY CORP PUT TRAMFORD NTL LTD ORD TRANSOCEAN INC ORD TRANSOCEAN INC CALL TRANSOCEAN INC PUT TRENWICK GROUP LTD COM TSAKOS ENERGY NAVIGATION LTD SHS Run Date: 412912003 ** List Of Section 13F Securities ** Page 5 Run Time: 1754 ISSUER NAME ISSUER DESCRIPTION STATUS GOLAR LNG LTD BERMUDA SHS WEATHERFORD IhTERN.4TIONAL LT COM WEATHERFORD INTERNATlONAL LT CALL WEATHERFORD INTERNATIONAL LT PUT WHITE MTNS INS CiROUP LTD COM WILLIS CiKOUP HOLDINGS LTD SI-IS WILLIS GROUP HOLDINGS LTD CALL WILLIS GROUP HOLDINGS LTD PUT XOMA LTD ORD XOMA LTD CALL XOMA LTD PUT XL CAP LTD CL A XL CAP LTD CALL XL CAP LTD PUT ALCON INC COM SHS ALCON INC CALL ALCON INC PUT UBS AG NAMEN AKT UBS AG CALL UBS AG PUT CRONOS GROUP N V ORD METRO INTERNATIONAL S A CL A METRO INTERNATIONAL S A CL B MILLICOM INTL CELLULAR S A ORD DELETED MILLICOM INTL CELLULAR S A CALL DELETED MILLICOM INTL CELLULAR S A PUT DELETED MILLICOM INTL CELLULAR S A SHS NEW ADDED SBS BROADCASTING SA ORD ACS TECH 80 LTD SHS ALADDM KNOWLEDGE SYS LTD ORD ALVARION LTD SHS ALVARION LTD CALL ALVAJUON LTD PUT AREL COMMUNICATIONS & SOFTWA COM ATTUNITY LTD ORD AUDIOCODES LTD ORD AUDIOCODES LTD CALL AUDIOCODES LTD PUT BACKWEB TECHNOLOGIES LTD ORD BACKWEB TECHNOLOGIES LTD CALL BACKWEB TECHNOLOGIES LTD PUT Run Date: 4/29/2003 ** List Of Section 13F Securities ** Page 6 Run Time: 17:54 ISSUER NAME ISSUER DESCRIPTION STATUS BARAN GROUP LTD NIS ORD SHS BOS BETTER ONLINE SOLUTIONS ORD ROB0 GROUP TEK LTD SHS BVR SYS LTD ORD DELETED BVR TECHNOLOGIES LTD ORD CAMTEK LTD om CERAGON NETWORKS LTD om CERAGON NETWORKS LTD CALL CERAGON NETWORKS LTD PUT CHECK POINT SOFTWARE TECH LT ORD CHECK POINT SOFTWARE TECH LT CALL CHECK POINT SOFTWARE TECH LT PUT CIMATRON LTD ORD CLICKSOFTWARE TECHNOLOGIES L ORD COMMTOUCH SOFTWARE LTD ORD COMMTOUCH SOFTWARE LTD CALL COMMTOUCH SOFTWARE LTD PUT COMPUGEN LTD ORD CRYSTAL SYS SOLUTIONS LTD ORD ECTEL LTD ORD ELBIT VISION SYS LTD ORD ELBIT SYS LTD ORD ELBIT SYS LTD CALL ELBIT SYS LTD PUT ELBIT MEDICAL IMAGING LTD ORD ELSCINT LTD NEW ORD ELTEK LTD ORD ENGELGENERALDEVELOPERSLTD ORD ETZ LAWLTD CL A ETZ LAVUD LTD COM PRECISE SOFTWARE SOLUTIONS L ORD PRECISE SOFTWARE SOLUTIONS L CALL PRECISE SOFTWARE SOLUTIONS L PUT FUNDTECH LTD ORD FUNDTECHLTD CALL FUNDTECH LTD PUT GILAT SATELLITE NETWORKS LTD ORD GILAT SATELLITE NETWORKS LTD CALL GILAT SATELLITE NETWORKS LTD PUT GIVEN IMAGING ORD SHS GIVEN IMAGING CALL Run Date: 4/29/2003 ** List Of Section 13F Securities ** Page 7 Run Time: 1754 ISSUER NAME ISSUER DESCRIPTION STATUS GIVEN IMAGING PUT WILL1 G FOOD INTL
Recommended publications
  • 2016 ANNUAL REPORT • ILLINOIS STATE BOARD of INVESTMENT Table of Contents

    2016 ANNUAL REPORT • ILLINOIS STATE BOARD of INVESTMENT Table of Contents

    2016 ANNUAL REPORT • ILLINOIS STATE BOARD OF INVESTMENT Table of Contents INTRODUCTION 2 Board Members 3 Letter to Trustees 8 Financial Highlights 9 Ten Year Summary FINANCIAL STATEMENTS 10 Independent Auditors’ Report 13 Financial Statements 14 Management’s Discussion and Analysis 16 Statement of Net Position 17 Statement of Changes in Net Position 18 Notes to Financial Statements SUPPLEMENTAL FINANCIAL INFORMATION 34 Portfolio of Investments 124 Portfolio Data 126 Investment Transactions with Brokers and Dealers 128 Restricted Investments 130 Staff and Investment Managers Printed on contract by authority of the State of Illinois, December 21, 2016 (100 copies at $28.80 each) ILLINOIS STATE BOARD OF INVESTMENT 1 Board Members Marc Levine Mark Cozzi Justice Mary Seminara-Schostok CHAIRMAN EXECUTIVE COMMITTEE Marc Levine Marc Levine Appointed Member Chairman VICE CHAIRMAN Mark Cozzi Mark Cozzi Vice Chairman Appointed Member Justice Mary Seminara-Schostok RECORDING SECRETARY Recording Secretary Justice Mary Seminara-Schostok James F. Clayborne Ezequiel Flores Chairman, Board of Trustees Shari Greco Reiches Judges’ Retirement System of Illinois Member at Large MEMBER-AT-LARGE AUDIT & COMPLIANCE COMMITTEE Shari Greco Reiches Justice Mary Seminara-Schostok Appointed Member Chairman Ezequiel Flores Senator James F. Clayborne Marc Levine, Board Chairman Chairman, Board of Trustees Shari Greco Reiches General Assembly Retirement System INVESTMENT POLICY COMMITTEE Michael Frerichs Mark Levine, Chairman Treasurer, State of Illinois Mark Cozzi Michael Frerichs Ezequiel Flores Susana A. Mendoza Susana A. Mendoza Steven Powell Comptroller, State of Illinois Chairman, Board of Trustees Shari Greco Reiches State Employees’ Retirement System EMERGING MANAGER COMMITTEE Steven Powell Senator James F. Clayborne, Chairman Appointed Member Mark Cozzi Ezequiel Flores Ezequiel Flores Michael W.
  • Bear Stearns & Co Inc

    Bear Stearns & Co Inc

    SECURITIES AND EXCHANGE COMMISSION FORM 13F-HR Initial quarterly Form 13F holdings report filed by institutional managers Filing Date: 2003-08-08 | Period of Report: 2003-06-30 SEC Accession No. 0000918134-03-000075 (HTML Version on secdatabase.com) FILER BEAR STEARNS & CO INC /NY/ Mailing Address Business Address 115 SOUTH JEFFERSON RD 115 SOUTH JEFFERSON RD CIK:918134| IRS No.: 133299429 | State of Incorp.:DE | Fiscal Year End: 0630 WHIPPANY NJ 07981 WHIPPANY NJ 07981 Type: 13F-HR | Act: 34 | File No.: 028-04239 | Film No.: 03832296 2017392202 Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document ---------------------------- OMB APPROVAL OMB Number: Expires: Estimated average burden hours per response..... ---------------------------- SEC USE ONLY ---------------------------- ---------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F Cover Page Report for the Calendar Year or Quarter Ended JUNE 30, 2003 If amended report check here: _ Amendment Number: This Amendment (Check only one.) _ is a restatement. _ adds new holding entries. Michael Wright -------------------------------------------------------------------------------- Name of Institutional Investment Manager Bear Stearns & Co. Inc. 115 South Jefferson Road Whippany NJ 07981 -------------------------------------------------------------------------------- Business Address (Street) (City) (State) (Zip) 13F File Number: 28-1496 The institutional investment
  • List of Section 13F Securities

    List of Section 13F Securities

    List of Section 13F Securities 1st Quarter FY 2004 Copyright (c) 2004 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2004, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2004. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by Section 13(f)(1) and Rule 13f-1 thereunder.
  • 2017 Immuno-Oncology Medicines in Development

    2017 Immuno-Oncology Medicines in Development

    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
  • Amy Liu, Et Al. V. Credit Suisse First Boston Corp., Et Al. 03-CV-20459

    Amy Liu, Et Al. V. Credit Suisse First Boston Corp., Et Al. 03-CV-20459

    ; fL V ~ UNITED STATES DISTRICT COUR ~ 2 0 9 SOUTHERN DISTRICT OF FLORID A Case No. CIV - MARTINE Z AMY LIU on behalf of herself and all others similarly situated, Plaintiff, vs. CREDIT SUISSE FIRST BOSTON CORPORATION, CREDIT SUISSE FIRST BOSTON, INCORPORATED, CREDIT SUISSE FIRST BOSTON-USA, CREDIT SUISSE FIRST BOSTON, CREDIT SUISSE GROUP, FRANK QUATTRONE, GEORGE BOUTROS, WILLIAM BRADY, JOHN M . HENNESSY, ALLEN D . WHEAT, RICHARD THORNBURGH, CHARLES WARD, DAVID A . DENUNZIO, EDWARD COMPLAINT-CLA§S,AGTION NADEL, JOHN HODGE, JACK TEJAVANIJA, JURY TRIAL DEMANDED AIRSPAN NETWORKS, INC ., ERIC D. STONESTROM, JOSEPH J . CAFFARELLI, AT ROAD, INC., KRISH PANU, THOMAS C. HOSTER, OCCAM NETWORKS INC . (formerly "ACCELERATED NETWORKS, INC ."), SURESH NIHALANI, FREDERIC T . BOYER, AVANTGO, INC., RICHARD OWEN, DAVID B . COOPER, JR ., AUTOWEB .COM, INC. (AUTOBYTEL, real party in interest), DEAN A . DEBIASE, SAMUEL M. HEDGPETH III, BSQUARE CORP ., WILLIAM T . BAXTER, BRIAN V. TURNER, BLUE COAT SYSTEMS, INC . (formerly "CACHEFLOW, INC."), BRIAN M. NESMITH, MICHAEL J. JOHNSON, CLARENT CORP. (VERSO TECHNOLOGIES, INC., real party in interest), JERRY SHAW-YAU CHANG, RICHARD J . HEAPS, COMMERCE ONE, INC., MARK B . HOFFMAN, PETER F . PERVERE, CORILLIAN CORP ., TED F. SPOONER, STEVEN SIPOWICZ, CENTILLIUM COMMUNICATIONS, INC., FARAJ AALAEI, JOHN W . LUHTALA, DIGITAL IMPACT, INC ., WILLIAM C. PARK, DAVID OPPENHEIMER, E MACHINES, INC ., \ yV-v STEPHEN A. DUKKER, STEVEN H . MILLER, EFFICIENT NETWORKS, INC., MARK A. FLOYD, JILL S . MANNING, E.PIPHANY, INC ., ROGER S . SIBONI, KEVIN J. YEAMAN, EVOLVE SOFTWARE, INC., JOHN P. BANTLEMAN, DOUGLAS S . SINCLAIR, HANDSPRING, INC., DONNA L. DUBINSKY, BERNARD J . WHITNEY, IMPROVENET, INC ., RONALD B. COOPER, RICHARD G.
  • Division of Investment Department of the Treasury State of New Jersey Pension Fund June 30, 2009 and 2008 (With Independent Auditors’ Report Thereon)

    Division of Investment Department of the Treasury State of New Jersey Pension Fund June 30, 2009 and 2008 (With Independent Auditors’ Report Thereon)

    F INANCIAL S TATEMENTS, M ANAGEMENT’ S D ISCUSSION AND A NALYSIS AND S UPPLEMENTAL S CHEDULES Division of Investment Department of the Treasury State of New Jersey Pension Fund June 30, 2009 and 2008 (With Independent Auditors’ Report Thereon) Division of Investment Department of the Treasury State of New Jersey Pension Fund Financial Statements June 30, 2009 and 2008 Contents Independent Auditors’ Report ..........................................................................................................1 Management’s Discussion and Analysis .........................................................................................3 Basic Financial Statements: Statements of Net Assets .................................................................................................................7 Statements of Changes in Net Assets...............................................................................................8 Notes to Financial Statements ..........................................................................................................9 Supplemental Schedules: Schedule 1 – Combining Schedule of Net Assets ..........................................................................31 Schedule 2 – Combining Schedule of Changes in Net Assets .......................................................32 Schedule 3 – Portfolio of Investments – Common Fund A ...........................................................33 Schedule 4 – Portfolio of Investments – Common Fund B ...........................................................57
  • 1. ARIN Ipv6 Wiki Acceptable Use

    1. ARIN Ipv6 Wiki Acceptable Use

    1. ARIN IPv6 Wiki Acceptable Use . 3 2. IPv6 Info Home . 3 2.1 Explore IPv6 . 5 2.1.1 The Basics . 6 2.1.1.1 IPv6 Address Allocation BCP . 6 2.1.2 IPv6 Presentations and Documents . 9 2.1.2.1 ARIN XXIII Presentations . 11 2.1.2.2 IPv6 at Caribbean Sector . 12 2.1.2.3 IPv6 at ARIN XXIII Comment . 12 2.1.2.4 IPv6 at ARIN XXI . 12 2.1.2.4.1 IPv6 at ARIN XXI Main-Event . 13 2.1.2.4.2 IPv6 at ARIN XXI Pre-Game . 14 2.1.2.4.3 IPv6 at ARIN XXI Stats . 14 2.1.2.4.4 IPv6 at ARIN XXI Network-Setup . 18 2.1.2.4.5 IPv6 at ARIN 21 . 21 2.1.3 IPv6 in the News . 21 2.1.3.1 Global IPv6 Survey . 23 2.1.3.2 IPv6 Penetration Survey Results . 23 2.1.4 Book Reviews . 25 2.1.4.1 An IPv6 Deployment Guide . 25 2.1.4.2 Day One: Advanced IPv6 Configuration . 25 2.1.4.3 Day One Exploring IPv6 . 25 2.1.4.4 IPv6 Essentials . 26 2.1.4.5 Migrating to IPv6 . 26 2.1.4.6 Running IPv6 . 26 2.1.4.7 IPv6, Theorie et pratique . 26 2.1.4.8 Internetworking IPv6 With Cisco Routers . 26 2.1.4.9 Guide to TCP/IP, 4th Edition . 26 2.1.4.10 Understanding IPv6, Third Edition . 27 2.1.5 Educating Yourself about IPv6 .
  • Listing of Global Companies with Ongoing Government Activity

    Listing of Global Companies with Ongoing Government Activity

    COMPANY LINE OF BUSINESS TICKER A & A BIOTECHNOLOGY S C ADAM BURKIEWICZ MIKOLAJ BURKIEWICZ PHARMACEUTICAL PREPARATIONS A & A GLOBAL INDUSTRIES, INC. AUTOMATIC VENDING MACHINES, NSK A & J ENTERPRISES PHARMACEUTICAL PREPARATIONS A & S INTERNATIONAL 2000 S.R.L. PHARMACEUTICAL PREPARATIONS A & S PHARMACEUTICAL CORP. PHARMACEUTICAL PREPARATIONS A & T MARKETING INC. COMPUTER INTEGRATED SYSTEMS DESIGN, NSK A & T SYSTEMS, INC. TELEPHONE COMMUNICATION, EXCEPT RADIO A & Z PHARMACEUTICAL INC. PHARMACEUTICAL PREPARATIONS A A INTERNATIONAL PHARMACEUTICAL PREPARATIONS A AND V, INC. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC A AROGYA HARBALS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS A B ENTERPRISES PHARMACEUTICAL PREPARATIONS A B I HERBAL PRODUCTS MEDICINALS AND BOTANICALS, NSK A B S REMEDIES PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK A BEAT FOR YOUR FEET, INC. COIN-OPERATED LAUNDRIES AND CLEANING, NSK A BUCKHEAD BUS COMPANY LOCAL PASSENGER TRANSPORTATION, NEC A C C VIEIRA PROTESE ME MEDICINALS AND BOTANICALS, NSK A C CONSULTING PHARMACEUTICAL PREPARATIONS A C E DIAGNOSTICS & BIOTECH LIMITED PHARMACEUTICAL PREPARATIONS A C E PHARMACEUTICALS PHARMACEUTICAL PREPARATIONS A C PHARMACEUTICALS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS A CUT ABOVE LANDSCAPE LAWN AND GARDEN SERVICES A D C O MARKETING INC NONDURABLE GOODS, NEC, NSK A G HERBALS PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK A G PHARMACEUTICALS PHARMACEUTICAL PREPARATIONS A H C PHARMACAL, INC PHARMACEUTICAL PREPARATIONS A H SYSTEMS INC INSTRUMENTS TO MEASURE ELECTRICITY A HOUSE OF AYURVEDIC
  • SHIRE PLC (Exact Name of Registrant As Specified in Its Charter)

    SHIRE PLC (Exact Name of Registrant As Specified in Its Charter)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PLC (Exact name of registrant as specified in its charter) Jersey (Channel Islands) 98-0601486 (State or other jurisdiction of incorporation or (I.R.S. Employer Identification No.) organization) 5 Riverwalk, Citywest Business Campus, Dublin +353 1 429 7700 24, Republic of Ireland (Address of principal executive offices and zip code) (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depositary Shares, each representing three NASDAQ Global Select Market Ordinary Shares 5 pence par value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) 1 Indicate by check mark whether the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act Yes [X] No [ ] Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act Yes [ ] No [X] Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
  • Bioworld Insight

    Bioworld Insight

    BioWorld Insight The news source of record covering the development of innovative human therapies October 30, 2017 Actionable Intelligence • Incisive Analysis Volume 25, No. 44 Society needs to urgently address antimicrobial resistance By Peter Winter, Editor The challenge of antimicrobial resistance (AMR) is one we need to urgently solve. In the U.S., the CDC estimates at least 2 million people become infected with bacteria that are resistant to currently available antibiotic therapies annually and approximately 23,000 people will die each year as a direct result of those infections. The threat of AMR has certainly been recognized worldwide and has become a top priority for global policy and public health. See AMR, page 3 Cheaper and faster also testing the drug in combination with immune Oncology drugs checkpoint inhibitors. “You often hear people say inhibiting PD-1 move to China seeking and CCR4 is like reducing the brake on a car. Plinabulin is like adding the fuel,” Huang patients and approvals explained. Nevertheless, she sees opportunities By Brian Orelli, Staff Writer for plinabulin in combination with both With a third of the world’s cancer patients residing chemotherapy and immune checkpoint inhibitors, Inside in China and upward of half of them enrolling in “Chemotherapy isn’t going away; nivolumab only clinical trials, small U.S.-based companies are has a 20 percent response rate.” Money raised by biotech looking across the Pacific to test their oncology On the neutropenia side, last week the company in 2017 drug candidates. enrolled its first patient in China in the global page 4 The advantages of lower cost and increased speed phase II/III trial testing plinabulin as a prevention of chemotherapy-induced neutropenia.
  • Lishing Group Group Nature Publishing

    Lishing Group Group Nature Publishing

    PEOPLE Paul L. Berns (left) has been appointed Allos Therapeutics’ NitroMed (Lexington, MA, USA) has (Westminster, CO, USA) president, CEO and member of the board announced that Argeris (Jerry) Karabelas, of directors. He brings close to 15 years of pharmaceutical industry currently chairman of the board of directors, experience to Allos, holding senior management positions at Abbott has been appointed interim CEO, succeed- Laboratories, BASF Pharmaceuticals and Bristol-Myers Squibb. Mr. ing Michael Loberg, who resigned from his Berns was most recently president, CEO and a member of the board position as president, CEO and director of of directors of Bone Care International. With Mr. Berns’ appointment, NitroMed. In addition, Kenneth Bate, formerly Michael E. Hart has resigned his positions as president, CEO and CFO of Millennium Pharmaceuticals, has been CFO, and David C. Clark, the company’s controller and treasurer, has named chief operating officer and CFO, follow- been appointed to serve as interim CFO until a permanent replacement is found. ing the departure of Lawrence Bloch as CFO and chief business officer. Morphotek (Exton, PA, USA) has announced Privately held NascaCell IP (Munich) has was most recently head of clinical operations the appointment of Robert Radie as chief announced the appointment of cofounder at Vical. business officer and the promotion of Luigi http://www.nature.com/naturebiotechnology Michael Blind to the position of CEO. Dr. Grasso to senior vice president of R&D. Mr. Blind was previously responsible for research VLST Corp. (Seattle, WA, USA) has announced Radie was most recently senior vice president and development activities at NascaCell.
  • Report Summarizing Select Media, Event Tech and Retail Tech Activity

    Report Summarizing Select Media, Event Tech and Retail Tech Activity

    REPORT SUMMARIZING SELECT MEDIA, EVENT TECH AND RETAIL TECH ACTIVITY DECEMBER 2018 0 THE MEDIA MONTHLY SPECIAL HIGHLIGHTS IN THIS ISSUE ▪ Amazon’s Advance Into Advertising ▪ The Age of the Distracted Viewer ▪ DOOH at Inflection Point ▪ The Future of Advertising and Why Outdoor is Back ▪ Proof of Play Standardization for Digital Out of Home ▪ AI: Collection of Technologies RECENT PJ SOLOMON TRANSACTIONS PENDING PENDING PENDING PENDING NOVEMBER 2018 A Consortium, including Has been sold to Sale to Has been sold to Sale to Has agreed to acquire Served as strategic and financial Serving as financial advisor to Serving as financial advisor to Best Serving as financial advisor to VSS- Serving as financial advisor to the advisor to Exterion Media and Martin’s Super Markets Market Southern Theatres / Movie Tavern Consortium Platinum Equity OCTOBER 2018 OCTOBER 2018 OCTOBER 2018 OCTOBER 2018 OCTOBER 2018 Sale of Has acquired Has divested Has been sold to Senior Secured Credit Facility to to Served as financial advisor to Served as financial advisor to Served as financial advisor to Served as financial advisor to V.F. Served as financial advisor to Bare SUPERVALU Key Food Hibbett Sports Corporation Necessities MEDIA SERVICES MARK A. BOIDMAN BEN ZINDER JONATHAN BERGER CHRISTIAN BERMEL Managing Director Director Senior Associate Senior Analyst 212.508.1661 (w) 212.508.1621 (w) 646.378.4062 (w) 646.708.8478 (w) 917.526.1092 (m) 646.522.8353 (m) 973.464.8979 (m) 860.371.5882 (m) [email protected] [email protected] [email protected] [email protected] Twitter: @MBoidman CAPITAL MARKETS JOE STEIN Managing Director 212.508.1662 (w) 203.550.2184 (m) [email protected] WWW.PJSOLOMON.COM 1 THE MEDIA MONTHLY AMAZON’S ADVANCE INTO ADVERTISING Amazon Expected to Mount Challenge to Google and Facebook in Digital Advertising ▪ Amazon 2018E ad sales expected to surpass ~$5.8 billion – #3 player in U.S.